Down 71%, Should You Buy the Dip on Viking Therapeutics Stock?

No one ever claimed investing in the biotech industry was a smooth ride, but for shareholders of Viking Therapeutics (VKTX -2.18%), the turbulence has been extremely challenging thus far. The stock is down 71% over the past year, amid ongoing uncertainties regarding the timeline for future commercialization of its clinical pipeline and the broader stock market sell-off.Nevertheless, the company's prospects remain positive with its portfolio of therapeutic candidates covering metabolic and endocrine diseases ...